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Overlap Syndrome of Functional Dyspepsia and 
Irritable Bowel Syndrome - Are Both Diseases 
Mutually Exclusive?
Hidekazu Suzuki* and Toshifumi Hibi
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
ㅋ
Among functional gastrointestinal (GI) disorders, functional dyspepsia (FD) and irritable bowel syndrome (IBS) are important to 
public health around the world and are frequently encountered in general practice. Upper GI symptoms such as heartburn, 
postprandial fullness, early satiety, epigastric pain or burning and lower GI symptoms such as constipation and diarrhea often 
coexist. Although the prevalence of FD-IBS overlap would be influenced by the selection of the study population, the overlap 
rate of FD-IBS could be in the range of 11%-27%. Specifically, FD-IBS overlap is associated with more severe symptoms than 
FD alone or IBS alone. Since clinical overlap, especially FD-IBS overlap, is very common, the 2 syndromes should not be treated 
in a mutually exclusive fashion.
(J Neurogastroenterol Motil 2011;17:360-365)
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Introduction
Epidemiological studies suggest a considerably high rate of 
overlap between functional dyspepsia (FD) and irritable bowel 
syndrome (IBS). According to the recent systematic review and 
metanalysis,
1 the prevalence of IBS in subjects with dyspepsia is 
37% (95% CI, 30%-45%) as compared to 7% (95% CI, 5%- 
10%) in those without. The pooled odds ratio for IBS in subjects 
with dyspepsia was 8 (95% CI, 5.74-11.16) as compared to that 
in those without dyspepsia. However, the original studies used an 
older classification such as Manning’s, Rome I or II, than Rome 
III and also did not exclude organic diseases, possibly resulting in 
the contamination with peptic ulcer diseases or reflux esophagitis. 
Prevalence of Overlap Between 
Functional Dyspepsia and Irritable 
Bowel Syndrome
There are a few evaluations of overlap between FD and IBS FD-IBS Overlap Syndrome
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based on the Rome III classification. Kaji et al
2 conducted a 
cross-sectional study to examine the prevalences of gastroeso-
phageal reflux, FD and IBS, their overlap rates, and the 
health-related quality of life (HRQOL) for each disease and each 
overlap syndrome, as compared with the corresponding values in 
healthy controls in a Japanese health check-up population. Of the 
2,680 eligible subjects, 269 (10.0%) were diagnosed as having 
FD, and 381 (14.2%) as having IBS. Overlaps between FD and 
IBS were found in 92 patients (3.4%). Overlap significantly 
worsened the HRQOL in most domains, except in the “role 
emotional” domain. The HRQOL was particularly poor in the 
mental component summary for overlapping IBS.
2 On the other 
hand, Nakajima et al
3 conducted a survey in a general gastro-
enterology outpatient clinic of 1,378 consecutive patients. Among 
them, 29 (2.1%) were diagnosed as having FD, and 33 (2.4%) as 
IBS. Overlaps between FD and IBS were found in 12 (0.9%).
Wang et al
4 investigated 3,014 patients who responded to 
their questionnaires (male:female = 47.2:52.8, response rate 
89%) at a general gastroenterology outpatient clinic. FD-IBS 
overlap was observed in 151 (5.0%) patients, while 457 (15.2%) 
and 329 (10.9%) were classified as having FD alone and IBS 
alone, respectively.
4 As compared with that in the non-IBS co-
horts, the OR of having FD among IBS was 2.09 (95% CI, 
1.68-2.59). Patients with FD-IBS overlap had higher severity 
scores for the symptom of postprandial fullness (2.4 ± 1.5 vs 1.7 
± 1.6, P ＜ 0.001) and overall FD symptoms (6.7 ± 2.9 vs 5.8 ± 
2.8, P ＜ 0.05) than those with FD alone. The only independent 
risk factor for FD-IBS overlap versus FD alone was the presence 
of postprandial fullness (OR, 2.67; 95% CI, 1.34-5.31).
4
Lee et al
5 investigated the differences in depressive mood and 
quality of life (QOL) among Korean patients with FD, IBS and 
FD-IBS overlap diagnosed by the Rome III definition. 
According to their report,
5 out of 279 subjects, 70 (25.1%) and 
124 (44.4%) were diagnosed as having FD and IBS, respectively. 
Patients with FD-IBS overlap and those with FD alone showed 
higher Beck Depressive Inventory scores than normal subjects (P 
＜ 0.001 and P = 0.02, respectively), whereas those with IBS 
alone showed no differences in scores from normal subjects (P = 
0.17). All of the SF-36 (the 36-item Short Form general health 
survey) subscores of the FD-IBS overlap cohorts were sig-
nificantly lower than those in normal subjects (P  ＜ 0.05). 
Depressive mood was significantly related to FD and FD-IBS 
overlap, but not to IBS alone. Patients with FD-IBS overlap had 
a worse QOL than patients with FD alone or IBS alone.
4 
Furthermore, according to the recent report by Park,
6 the sensi-
tivity and specificity of the Rome III classification in discriminat-
ing functional gastrointestinal disorders (FGIDs) from organic 
diseases of the upper gastrointestinal (GI) tract were 60% and 
53%, respectively, while the values of the lower GI tract were 
80% and 50%, respectively, partially supporting the use of the 
Rome III criteria in Korea.
5
Data on the impact of FD on the HRQOL in the general 
population are scarce. Aro et al
7 explored the impact of FD based 
on the Rome III classification on the HRQOL in the general 
population. Among 1,001 cohorts, 202 (20%) individuals re-
ported uninvestigated dyspepsia (UID), and 157 (16%) reported 
FD. FD-IBS overlap had a significant impact on bodily pain (P 
＜ 0.01) and general health (P ＜ 0.05).
7
Although Hori et al
8 used the Rome II criteria, they exam-
ined concurrent GI symptoms in FD and IBS in a total of 186 
college students who filled out a questionnaire administered to 
determine whether they had UID or IBS. The diagnosis of UID, 
IBS and UID ＋ IBS overlap was made in 12 (6.7%), 40 
(22.1%) and 8 (4.4%) patients, respectively and a significant 
prevalence of UID ＋ IBS overlap was observed (66.7% IBS in 
UID; 20.0% UID in IBS).
8 Although Corsetti et al
9 also used 
Rome II criteria for the diagnosis of FD in their questionnaire 
survey of 309 consecutive FD patients to assess the dyspepsia and 
IBS symptom patterns, 54% of the patients had FD alone, where-
as 46% had FD ＋ IBS. FD-IBS overlap patients were more 
likely to be female (75% vs 60%, P ＜ 0.01) and to have greater 
weight loss (5.4 ± 0.6 vs 3.5 ± 0.4 kg, P ＜ 0.05). Coexisting 
IBS did not increase the risk of dyspepsia, however, the overall 
symptom severity was significantly higher in the patients with 
FD-IBS overlap (12.4 ± 0.4 vs 9.8 ± 0.3, P ＜ 0.01). FD-IBS 
overlap patients had a lower threshold for first perception (2.9 ± 
0.3 vs 3.8 ± 0.3 mmHg, P ＜ 0.05) and for discomfort (7.9 ± 
0.4 vs 9.5 ± 0.5 mmHg, P ＜ 0.05) and a greater prevalence of 
hypersensitivity to gastric distention (44% vs 28%, P ＜ 0.05).
9
Recently, we performed a web-based survey comprised of 
Rome III criteria for FD, the Gastrointestinal Symptom Rating 
Scale, and questions to determine demographic information 
among subjects registered for Japanese clinical trial programs.
10 
Cluster analysis revealed 3 distinct clusters: cluster associated 
with diarrhea, cluster associated with constipation and cluster as-
sociated with neither diarrhea nor constipation. Cluster asso-
ciated with constipation and cluster associated with diarrhea were 
significantly linked to the presence of FD, suggesting that FD 
was more prevalent among participants with bowel symptoms 
than in those without. Furthermore, FD patients with bowel Hidekazu Suzuki and Toshifumi Hibi
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Table. Prevalence of Overlap Between Functional Dyspepsia and 
Irritable Bowel Syndrome
FD alone 
(n [%])
IBS alone 
(n [%])
FD-IBS overlap 
(n [%])
Wang et al
4 306 (48.2) 178 (28.0) 151 (23.8)
Nakajima et al
3   17 (34.0)   21 (42.0)   12 (24.0)
Kaji et al
2 177 (31.7) 289 (51.8)   92 (16.5)
Lee et al
5   28 (18.4)   82 (53.9)   42 (27.6)
Park
6   72 (43.1)   76 (45.5)   19 (11.4)
FD, functional dyspepsia; IBS, irritable bowel syndrome.
symptoms had more severe dyspepsia symptoms than those 
without.
Although GI symptoms are quite common in the general 
population, different methods for the survey show different epi-
demiologies, and the effects of psychosocial and behavioral fac-
tors on the symptoms have been studied, mainly by subgroup 
analysis. According to the Japanese questionnaire survey focus-
ing on GI symptoms and the psycho-behavioral background in 
members of a registered panel via e-mail and postal mail, despite 
the difference in the prevalence of GI symptoms, that is, 47% in 
the electronic survey and 25% in the postal one, similar pro-
portions of symptom subtypes and patterns of overlaps were ob-
tained with such 2 methods.
11 While 56% were diagnosed as hav-
ing FD, and 58% as having IBS in the electronic survey, 57% 
were diagnosed as having FD, and 55% as having IBS in the 
postal one. FD-IBS overlap was found in 24% in the electronic 
survey and in 23% in the postal one. Subjects who have higher 
scores for psycho-behavioral problems had a higher prevalence of 
FD and IBS symptoms. The data suggest that psycho-behavioral 
conditions may affect the development of functional GI symp-
toms, regardless of the subtype of GI disorders, and can explain 
the high proportion of overlap among the subtypes.
11
Taken together, the above-mentioned prevalence of FD-IBS 
overlap would be altered depending on the selected study 
population. The rate of FD-IBS overlap could be in the same 
r a n g e ,  s u c h  a s  1 1 . 4 % ,
6 16.5%,
2 23.8%,
4 24.0%
3 and 27.6%
5 
(Table).
Influence of Each Subtype of Functional 
Dyspepsia or Irritable Bowel Syndrome 
on the Presence of Functional Dyspepsia- 
Irritable Bowel Syndrome Overlap
A general definition of FD, to be used mainly for clinical 
purposes, and although further research on more specific defi-
nitions is ongoing, is provided under category B1: functional dys-
pepsia (FD) in Rome III classification. However, particularly for 
pathophysiological and therapeutic approach, it is recommended 
in Rome III that new entities of meal-induced dyspeptic symp-
toms as postprandial distress syndrome (PDS): B1a, and epi-
gastric pain and burning as epigastric pain syndrome (EPS): 
B1b, should be used.
12 These 2 subcategories such as PDS and 
EPS seem very useful in clinical practice as well as in the inves-
tigative settings. According to the report by Wang et al,
4 more 
patients with PDS alone had IBS than those with EPS alone. 
Patients with FD-IBS overlap were more likely to be classified as 
the PDS ＋ EPS subtype, had more frequent presence of the 
postprandial fullness symptom, one of major symptoms of PDS 
(P ＜ 0.001), and overall FD symptom (P ＜ 0.01) than those 
with FD alone. Furthermore, patients with FD-IBS overlap were 
less likely to be classified as the EPS alone (P ＜ 0.01) compared 
to those classified as FD alone. By the multivariate logistic re-
gression analysis, only the presence of postprandial fullness (OR, 
2.67; 95% CI, 1.34-5.31; P ＜ 0.01) had a statistically significant 
and independent effect on the probability of FD-IBS overlap. On 
the other hand, subtypes of IBS did not differ between patients 
with constipation type-IBS (IBS-C) and diarrhea-type IBS 
(IBS-D). In addition, neither IBS-D (OR, 1.44; 95%CI, 
0.93-2.22; P = 0.10) nor mixed-type IBS (IBS-M) (OR, 1.62; 
95% CI, 0.77-3.40; P = 0.21) was identified as risk factor for 
FD-IBS overlap versus IBS alone in the multivariable analysis. 
Aro et al
7 reported the data on the impact of PDS and EPS on 
QOL. The impact of PDS is statistically significant compared 
with controls except for Role Emotional and the results are con-
sistently the same when analyzing for the possible confounders 
such as anxiety, depression and use of proton pump inhibitors. 
Patients with EPS had a statistically relevant impairment of 
HRQOL only in 2 domains such as Bodily Pain and Vitality 
compared with nondyspeptic cohorts. Namely, PDS seems to 
damage HRQOL in all SF-36 domains more than EPS.
In addition, non-erosive relux disease is more frequently 
overlapped with FD, especially with EPS and presents with sig-
nificantly increased frequency of IBS.
13
Pathophysiology Leading to Functional 
Dyspepsia-Irritable Bowel Syndrome 
Overlap
FD and IBS are common functional disorders without de-FD-IBS Overlap Syndrome
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fined pathophysiology and are known as multifactorial synd-
romes. The pathophysiological factors for the generation of FD 
or IBS would be listed as visceral hypersensitivity, central abnor-
mal deregulation for sensory perception, GI dysmotility, and ab-
normal alteration of the intestinal flora, GI inflammation, and 
psychosocial factors. Although such a mechanistic investigation is 
further preceded in the research field in IBS, the detail of patho-
physiology in FD-IBS overlap has not been fully explored. 
However, as these 2 syndromes (FD and IBS) would have com-
mon causative factors, the high prevalence of FD-IBS overlap is 
considered to be easily acceptable.
Abnormalities of psychosocial or central nervous factors, 
which would affect the whole GI tract, could be a possible causa-
tive factor in the pathogenesis of FD-IBS overlap. Savas et al
14 
examined the 1-year prevalence of IBS and dyspepsia symptoms 
and their associations with depression, anxiety and post-traumatic 
stress disorder (PTSD) among women veterans receiving pri-
mary care at a Women’s Clinic, Veteran Affairs (VA) Medical 
Center. They reported that women with IBS-dyspepsia overlap 
showed higher scores of anxiety (IBS: 24 vs 12, P ＜ 0.001 and 
dyspepsia: 26 vs 12, P ＜ 0.001), depression (IBS: 22 vs 11, P 
＜ 0.001 and dyspepsia: 23 vs 11, P ＜ 0.001) and PTSD (IBS: 
87 vs 69, P ＜ 0.001 and dyspepsia: 86 vs 69, P ＜ 0.0005), and 
age- and ethnicity-adjusted logistic regression analyses revealed a 
3- to 46-fold increase in the OR of IBS and dyspepsia among 
women with depression, anxiety or PTSD.
14 Although gastric 
sensorimotor dysfunction, psychosocial factors and somatization 
are all implicated in the development of FD symptoms according 
to the report by Van Oudenhove et al,
15 symptom severity and 
w e i g h t  l o s s  i n  F D  a r e  d e t e r m i n e d  b y  p s y c h o s o c i a l  f a c t o r s  
(depression or history of abuse) and somatization, and to a lesser 
extent by gastric sensorimotor function, but not by FD-IBS 
overlap. On the other hand, Kindt et al
16 in Belgium investigated 
the 5-year evolution of symptoms in a clinical FD population to 
identify factors associated with the outcome and indicated that the 
dyspepsia symptom score (DSS) at the initial visit and trait anxi-
ety were longitudinally associated with the DSS at follow-up, with 
a trend found for weight loss; depression, chronic fatigue and 
IBS at follow-up were cross-sectionally associated with DSS.
On the other hand, GI inflammation and altered immune re-
sponses could be another candidate as the cause of FD-IBS 
overlap. Patients with IBS show a greater degree of inflammatory 
cell infiltration than healthy controls. Mast cells and eosinophils 
interact with T lymphocytes and may alter the enteric nerve and 
smooth muscle functions. Examination of 48 IBS patients with 
either diarrhea or constipation,
17 12 patients with microscopic 
colitis, 20 patients with ulcerative colitis, and 24 healthy controls, 
indicated that as compared to male IBS patients, female IBS had 
greater numbers of mast cells (P = 0.066), but lesser numbers of 
CD3＋ and CD8＋ T cells (P ＜ 0.01 and P ＜ 0.001, re-
spectively). Such mucosal mast cell infiltration in IBS patients 
was significantly associated with the frequency of abdominal 
bloating (P ＜ 0.05) and with dysmotility-like dyspepsia (P = 
0.001), but not with ulcer-like dyspepsia.
17 According to the re-
port by Walker et al,
18 intraepithelial lymphocytes in IBS-C were 
significantly increased (P = 0.005) and mast cells were sig-
nificantly increased in the second part of the duodenum in IBS (P 
＜ 0.001), while eosinophils were significantly increased in the 
duodenal bulb and second part of the duodenum in FD (P ＜ 
0.001), suggesting that duodenal mast cell hyperplasia is linked 
to IBS, and eosinophilia to FD.
Recently, it has been revealed that previous infectious gastro-
enteritis is often followed by postinfectious FD (PI-FD)
19 or 
postinfectious IBS (PI-IBS).
20 Porter et al
21 recently conducted a 
matched, case-control study describing the epidemiology and risk 
determinants of IBS, functional constipation, functional diarrhea 
and dyspepsia using electronic medical encounter data in ac-
tive-duty US military personnel, and demonstrated a significant 
association between infectious gastroenteritis and all FGIDs 
(OR, 2.64; P ＜ 0.001), with the highest frequency of functional 
diarrhea (OR, 6.28; P ＜ 0.001) and IBS (OR, 3.72; P ＜ 
0.001), and a moderate frequencies of functional constipation 
(OR, 2.15; P  ＜ 0.001) and FD (OR, 2.39; P  ＜ 0.001). 
According to Kindt et al
22 and Suzuki
23, PI-FD is associated 
with persistent focal T cell aggregates, decreased CD4＋ cells 
and increased macrophage counts surrounding the crypts, in-
dicating an impaired ability of the immune system to terminate 
the inflammatory response after an acute insult.
Since the etiology of FD is still uncertain, it is not surprising 
that Helicobacter pylori, a major pathogen in the stomach,
24-26 has 
been implicated in the pathophysiology of so called dyspepsia. 
Many trials reporting the efficacy of H. pylori eradication therapy 
for FD including non-ulcer dyspepsia have given conflicting re-
sults but there is a clear indication that H. pylori eradication treat-
ment is effective in at least a subset of patients with FD or non-ul-
cer dyspepsia.
27,28 The recent meta-analysis also suggests that H. 
pylori eradication at 12 months has a small but statistically sig-
nificant benefit in the treatment of FD (relative risk [RR] of re-
maining dyspepsia with H. pylori eradication therapy = 0.91; 
95% CI, 0.87-0.99). While statistically significant, the clinical Hidekazu Suzuki and Toshifumi Hibi
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significance of this finding is less clear because the effect is small, 
that is, 15 H. pylori-positive dyspeptic patients will need to be 
treated to achieve just one cure.
29 On the other hand in Asia, 
Gwee et al
30 conducted a double blind, randomized, placebo-con-
trolled trial of H. pylori eradication for FD was conducted in 
Singapore population. Forty-one patients received active treat-
ment consisting of a 1-week course of omeprazole 20 mg once 
daily, clarithromycin 250 mg twice daily and tinidazole 500 mg 
twice daily whereas another 41 patients received matching place-
bo tablets. They reported on ITT analyses, that while symptom 
resolution was observed in 24% of patients on active treatment, 
only 7% was found on the placebo (P = 0.02; 95% CI, 1.1-17.7). 
In addition, their report shows that among patients with H. pylori 
eradicated on active treatment the symptom resolution rate was 
39%, whereas it was 3% among patients in the placebo who had 
persistent H. pylori infection,
30 suggesting that patients with FD 
in Asian population might benefit more from treatment for H. py-
lori infection.
On the aspects of pathophysiology of dyspepsia in H. pylori 
infection, we recently reported in mice that after long-term H. py-
lori infection, gastric emptying was significantly accelerated with 
a significant thickening of the muscular layers of the stomachs 
that was manifest in the hyperplasia of myocytes.
31 We also exam-
ined the expression profile of microRNAs (miRs), which is re-
cently reported to be involved in the pathogenesis of GI disorders 
including cancers.
32,33 In H. pylori-infected mice, the muscle-spe-
cific miRs such as miR-1, miR-133a and miR-133b were sig-
nificantly down-regulated in the stomachs with an enhancement 
of the expression of histone deacetylase 4 and serum response fac-
tor, which are reported target genes of miR-1 and miR-133 and to 
enhance the muscular hyperproliferation. Accelerated gastric 
emptying may be possibly through the disturbed gastric accom-
modation due to the alterations in muscular layer modification, 
providing a novel insight into the molecular pathogenesis of dys-
pepsia associated with H. pylori infection.
31
There might be a reason to consider H. pylori-associated dys-
pepsia as an organic disease and to deal with it as a different dis-
ease entity from FD.
34,35 A new classification based on the patho-
physiology and specific symptoms needs to be considered to fur-
ther the diagnostic and therapeutic advances in this field.
Racial Differences in the Epidemiology 
of Irritable Bowel Syndrome and 
Dyspepsia
There is a paucity of data on racial differences in the epidemi-
ology of IBS alone and UID alone as compared to that of the 
“overlap syndrome.” According to a random survey of 990 sub-
jects who completed a questionnaire which included the Rome II 
criteria for IBS and FD,
35 among African Americans, the preva-
lences of IBS alone, UID alone and their overlap were 0.6%, 
17% and 7.3%, respectively, while among Caucasian Americans, 
they were 0%, 13% and 13%, respectively. All but 4 patients with 
IBS had UID. Among patients with UID, overlap syndrome was 
seen in 30% of African Americans, as compared to 50% of 
Caucasian Americans. African Americans below the poverty line 
were more likely to have UID than overlap (22% vs 10%). As 
compared to African Americans, Caucasians with overlap syn-
drome were likely to be married and to be living in an urban area. 
There was a higher prevalence of overlap syndrome (UID-IBS) 
among Caucasians with lower levels of education. UID-IBS 
overlap was 2.5 times more likely to occur among Caucasians 
than among African Americans.
36 However, among UID pa-
tients, there might be considerable numbers of patients with pep-
tic ulcer disease or erosive esophagitis.
Conclusion
The concept of FD-IBS overlap syndrome is important for 
determining the independent therapeutic approach for such dis-
ease conditions of FD alone or of IBS alone, by treating them as a 
disease of the entire gut as a single organ. Under such concept of 
disease overlap, FD and IBS can be recognized as being fre-
quently coexisting and not mutually exclusive syndromes.
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